NCT01079871View on ClinicalTrials.gov

Evaluation of FID 114657 in Sjogren's Syndrome Subjects

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

June 30, 2010

Conditions
Sjogren's Syndrome
Interventions
OTHER

FID 114657 (ORB Preserved Ocular Emulsion)

Patients will dose as needed throughout the day (PRN) for 4 weeks.

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY